comparemela.com

Jacobin Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting

Jacobin Pharma announced that the company will present the results of two preclinical evaluation of PARP7 inhibitor JAB-26766 and p53 Y220C reactivator JAB-30355 in form of the abstract during the.

United statesSan diegoAmerican association for cancer researchJacobin pharmaAmerican associationCancer researchAnnual meetingPoster presentationAntitumor agents

Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting

/PRNewswire/ Jacobin Pharma (1167.HK) today announced that the company will present the results of three preclinical studies of KRASmulti inhibitor.

United statesJacobio pharmaAmerican association for cancer researchJacobin pharmaAmerican associationCancer researchAnnual meetingNovel antitumor agentsTherapeutic antibodiesInduced allosteric drug discovery platform

vimarsana © 2020. All Rights Reserved.